Muhammad Khan, MD, is a seasoned professional with over 20 years of experience in drug development, particularly in Hematology and Oncology, with a focus on advanced solid tumors. Currently serving as the Director of Medical & Scientific Affairs at ICON plc, Muhammad has provided medical monitoring oversight for pivotal studies that led to FDA approvals and has a keen interest in the development of antibody-drug conjugates. Previously, Muhammad held significant roles at McKesson Specialty Health, PRA Health Sciences, and Weill Cornell Medical College, contributing to the advancement of translational oncology research. Muhammad actively participates in the American Association for Cancer Research and the American Society of Clinical Oncology and has authored numerous abstracts and publications, presenting research at notable conferences such as ASCO.
This person is not in any offices